Anavex Life Sciences Corp (AVXL)

[JB3729]

No way Anavex presents previously disclosed info at AAIC. Premier conferences don't allow it. An example from ASCO -

CHICAGO – A presentation at the annual meeting of the American Society of Clinical Oncology by Immunomedics (IMMU) has been rejected after it was discovered the company was trying to use old and previously presented data for its triple negative breast cancer drug IMMU-132, thestreet reported this morning.

Presenting old data as new is against the rules of ASCO, thestreet’s Adam Feuerstein reported. The presentation, which can currently be found on Immunomedics’ website, was previously presented at a network meeting in April. That information was also discussed on a conference call with investors, Feuerstein said. ASCO accepted the abstract on the premise it contained new or updated information. Aditya Bardia of Harvard Medical School, the lead investigator of IMMU-132, told thestreet that she was unaware of the previous presentation of the data.
http://www.biospace.com/news_story.aspx?StoryID=421981


Breaking: ASCO removes $IMMU late-breaker IMMU-132 presentation in TNBC from #ASCO16 due to company violating abstract confidentiality. (h/t @adamfeuerstein)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123061617&txt2find=immu